Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Cash from Operations (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Cash from Operations for 5 consecutive years, with 7361000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Operations rose 54.63% to 7361000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 34145000.0, a 56.06% increase, with the full-year FY2024 number at 70011000.0, down 10.59% from a year prior.
  • Cash from Operations was 7361000.0 for Q3 2025 at Lyra Therapeutics, down from 6590000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 3381000.0 in Q2 2021 to a low of 22455000.0 in Q1 2024.
  • A 5-year average of 11858578.95 and a median of 11352000.0 in 2024 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: crashed 350.52% in 2022, then surged 67.02% in 2025.
  • Lyra Therapeutics' Cash from Operations stood at 11297000.0 in 2021, then dropped by 7.67% to 12164000.0 in 2022, then plummeted by 56.68% to 19058000.0 in 2023, then surged by 40.43% to 11352000.0 in 2024, then skyrocketed by 35.16% to 7361000.0 in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Cash from Operations are 7361000.0 (Q3 2025), 6590000.0 (Q2 2025), and 8842000.0 (Q1 2025).